Navigation Links
Stem cell therapy may help severe congestive heart failure
Date:3/13/2014

Augusta, Ga. Researchers want to know whether patients with debilitating heart failure can benefit by having their own stem cells injected into their ailing heart muscle.

The severe condition is ischemic dilated cardiomyopathy, a currently incurable condition resulting from significantly compromised blood flow to the heart muscle as well as heart attacks, which leave the muscle bulky and inefficient and patients unable to carry out routine activities.

"We want to know if stem cell therapy is an option for patients who have essentially run out of options," said Dr. Adam Berman, electrophysiologist at the Medical College of Georgia at Georgia Regents University and Director of Cardiac Arrhythmia Ablation Services at Georgia Regents Health System. "It's a very exciting potential therapy, and these studies are designed to see if it works to help these patients."

Berman is a Principal Investigator on the multi-site study in which stem cells are removed from the bone marrow, their numbers significantly increased by technology developed by Aastrom Biosciences, then injected into multiple weak points in the heart. At GR Health System, the procedure is performed in the Electrophysiology Lab where Berman threads a catheter into an artery from the groin into the heart. Three-dimensional maps of the heart are created to provide a clear picture of its natural geography as well as major sites of damage.

"Everyone's heart is different, their scar burden is different, everything is different," Berman said. From that vantage point, small needles - similar in size to those used for skin testing - are used to make about 12 to 20 strategic injections of mesenchymal stem cells, which can differentiate into a variety of cell types. In this case, researchers hope the cells will improve blood flow and function of the heart.

Half of the study participants receive the stem cell treatment called ixmyelocel-T and the remainder a saline placebo. Patients go home the next day but researchers follow all participants for 12 months to assess heart function and quality of life. GR Health System plans to enroll a handful of patients in the clinical trial.

Treatment options for heart failure include frontline therapies such as diuretics to more extreme measures such as implantable ventricular assist devices and heart transplants.

Patients eligible for this trial have explored existing options and must have an internal defibrillator, a standard of care in these patients to help avoid sudden death from an abnormal heart rhythm. Sudden death and progressive heart muscle failure cause most congestive heart failure deaths. Before enrollment, a cardiothoracic surgeon and interventional cardiologist rule out other options to open the patient's coronary arteries.

While much work remains, Berman hopes stem cell therapy may one day be a part of early intervention to help keep heart failure from progressing to an advanced, debilitating state. "We hope this is the future," he said.

Laboratory studies at MCG and elsewhere indicate that stem cells injected into the heart typically survive only a week or two. "That has been a very debated point," said Dr. Neal Weintraub, cardiologist and Associate Director of MCG's Vascular Biology Center. So while evidence is limited that many stem cells actually turn into new heart cells, good evidence exists that they can help generate new blood vessels to reperfuse the heart and secrete factors that aid survival of existing heart cells, Weintraub said.

The sometimes dramatic change researchers see after injecting stem cells into the heart, at least in the laboratory, likely results from a combination of new and saved tissue, he said.

"What they do is produce a lot of factors that change the environment dramatically and conduce the normal cells in the tissue to work better and potentially help them survive," Weintraub said. His laboratory studies stem cells endogenous to the heart to learn more about how they work normally and how, in the future, they might be used therapeutically.

"If we can unlock the secrets, we might be able to teach the cells to do this repair on their own," Weintraub said. In fact, stem cells are found throughout the body, and while evidence suggests they already try to help repair damage, many patients have multiple related conditions, such as high blood pressure and diabetes, that prevent endogenous stem cells from working as well as they should, said Weintraub, who is a Co-Investigator on the new clinical study.

Unlike most clinical trials, Berman notes that if this study results are positive, participants who received placebo can also get ixmyelocel-T.


'/>"/>

Contact: Toni Baker
tbaker@gru.edu
706-721-4421
Medical College of Georgia at Georgia Regents University
Source:Eurekalert  

Related biology news :

1. Plant extract offers hope for infant motor neuron therapy
2. Enhancement of chemotherapy by prevention of tumor cell repair
3. Laboratory detective work points to potential therapy for rare, drug-resistant cancer
4. Mouse study shows gene therapy may be possible cure for Hurler syndrome
5. Scripps scientist awarded $1.8 million to develop new approaches to lung cancer therapy
6. International patient alliance to fund Spanish Friedreichs ataxia gene-therapy project
7. Ottawa researchers discover new combination therapy to kill cancer
8. Moderate doses of radiation therapy to unaffected breast may prevent second breast cancers
9. Nature study discovers chromosome therapy to correct a severe chromosome defect
10. Final agenda available for CRF Conference on Stem Cell Therapy for Heart Disease
11. Novel noninvasive therapy prevents breast cancer formation in mice
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Stem cell therapy may help severe congestive heart failure
(Date:4/5/2017)... , April 5, 2017 Today HYPR ... that the server component of the HYPR platform is ... providing the end-to-end security architecture that empowers biometric authentication ... HYPR has already secured over 15 million users across ... manufacturers of connected home product suites and physical access ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/30/2017)... -- Trends, opportunities and forecast in this market to ... AFIS, iris recognition, facial recognition, hand geometry, vein recognition, ... industry (government and law enforcement, commercial and retail, health ... and by region ( North America , ... , and the Rest of the World) ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... ... Disappearing forests and increased emissions are the main causes of the evolving air ... living in larger cities are affected by air pollution related diseases. , That is ... globally - decided to take action. , “I knew I had to take action ...
(Date:10/10/2017)... , ... October 10, 2017 , ... ... Center’s FirstHand program has won a US2020 STEM Mentoring Award. Representatives of the ... for Excellence in Volunteer Experience from US2020. , US2020’s mission is to change ...
(Date:10/10/2017)... ... October 10, 2017 , ... The Pittcon Program ... honoring scientists who have made outstanding contributions to analytical chemistry and ... 2018, the world’s leading conference and exposition for laboratory science, which will be ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... medical journal, Epilepsia, Brain Sentinel’s SPEAC® System which uses the surface electromyography ... generalized tonic-clonic seizures (GTCS) using surface electromyography (sEMG). The prospective multicenter phase ...
Breaking Biology Technology: